Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05852691 |
|---|---|
| Brief Title: | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer |
| First Submitted : | May 2, 2023 |
| First Submitted that Met QC Criteria : | May 2, 2023 |
| First Posted : | May 10, 2023 |
| Last Update Submitted that Met QC Criteria : | May 20, 2024 |
| Last Update Posted : | May 21, 2024 (Estimate) |